Disease · MONDO_0021085

gastric neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastric neoplasm. Diseases, record MONDO_0021085. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021085

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastric neoplasm; Open Targets
Open Targets ID: MONDO_0021085; Open Targets
Other names: Cancer of Stomach, Cancer of the Stomach, Cancer, Gastric, Cancer, Stomach, Cancers, Gastric, Cancers, Stomach, GASTRIC NEOPL, Gastric Cancer, Gastric Cancers, Gastric Neoplasms, NEOPL GASTRIC, NEOPL STOMACH, Neoplasm, Gastric, Neoplasm, Stomach, Neoplasms, Gastric, Neoplasms, Stomach, STOMACH NEOPL, Stomach Cancer, Stomach Cancers, Stomach Neoplasms, gastric tumor, gastric tumour, neoplasm of stomach, neoplasm of the stomach, stomach neoplasm, stomach neoplasm (disease), stomach tumor, stomach tumour, tumor of stomach, tumor of the stomach, tumour of stomach, tumour of the stomach; Open Targets
MeSH: D013274; MeSH
NCI Thesaurus: C3387; NCI Thesaurus
Highest stage of its drugs: Approval, for 10 of its 83 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs83

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CAPECITABINE	CHEMBL1773	Small molecule	Approval	EMA Human Drugs	15	10	10	Drugs and targets
GIMERACIL	CHEMBL1730601	Small molecule	Approval	EMA Human Drugs	8	7	0	Drugs and targets
OTERACIL	CHEMBL181932	Small molecule	Approval	EMA Human Drugs	8	7	1	Drugs and targets
TEGAFUR	CHEMBL20883	Small molecule	Approval	EMA Human Drugs	8	7	1	Drugs and targets
TISLELIZUMAB	CHEMBL4297840	Antibody	Approval	EMA Human Drugs	5	4	4	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Approval	EMA Human Drugs	8	2	2	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Approval	EMA Human Drugs	12	1	1	Drugs and targets
RAMUCIRUMAB	CHEMBL1743062	Antibody	Approval	EMA Human Drugs	2	1	1	Drugs and targets
LENIOLISIB	CHEMBL3643413	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ZOLBETUXIMAB	CHEMBL2109427	Antibody	Approval	EMA Human Drugs	1	0	0	Drugs and targets

1 to 10 of 83

See all 83 drugs

Targets146

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	8	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	5	Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent	Approval	https://conductscience.org/library/genes/2064	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
TOP1	DNA topoisomerase 1	4	DNA topoisomerase I inhibitor	Phase 2	https://conductscience.org/library/genes/7150	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
TUBA1A	Tubulin	3	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin disrupting agent; Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 146

See all 146 targets

Trials65

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00400179	A Safety and Efficacy Study in Patients With Gastric Cancer	Phase 3	1,053	2012-04-23	Gastric Cancer	CISPLATIN, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT03382600	Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)	Phase 2	100	2023-12-01	Gastric Cancer	CISPLATIN, OTERACIL, OXALIPLATIN, PEMBROLIZUMAB, TEGAFUR	Its record names the disease	ClinicalTrials.gov
NCT04082364	Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer	Phase 2/3	82	2025-04-22	Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer	MARGETUXIMAB, RETIFANLIMAB, TEBOTELIMAB	Its record names the disease	ClinicalTrials.gov
NCT05014828	To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors	Phase 2	58	2025-08-24	Advanced Solid Tumor	LENVATINIB, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01178944	Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	Phase 2	35	2017-12-13	Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma	OXALIPLATIN, PRALATREXATE	Its record names the disease	ClinicalTrials.gov
NCT00514020	Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer	Phase 2	33	2012-10-18	Gastric Cancer	FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00496860	Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies	Phase 1	26	2013-07-15	Progressive Metastatic Malignancies	PEMVIDUTIDE	Its record names the disease	ClinicalTrials.gov
NCT01212822	Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer	Phase 2	20	2022-09-07	Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus, Stage IA Esophageal Cancer, Stage IA Gastric Cancer, Stage IB Esophageal Cancer, Stage IB Gastric Cancer, Stage IIA Esophageal Cancer, Stage IIA Gastric Cancer, Stage IIB Esophageal Cancer, Stage IIB Gastric Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer	BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT04798781	Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma	Phase 2	16	2024-10-10	Gastric Cancer, Hepatocellular Carcinoma	PEMBROLIZUMAB, TELATINIB	Its record names the disease	ClinicalTrials.gov
NCT02830594	Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer	Phase 2	14	2022-06-30	Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 65

See all 65 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
S-1/Cisplatin vs 5-FU/Cisplatin: serious adverse events	257 of 521	248 of 508	1,029	NCT00400179	Trial comparisons
Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) vs Pembrolizumab + Cisplatin +TS-1 (Cohort 2): Number of Participants With ≥1 Adverse Event (AE)	54 of 54	46 of 46	100	NCT03382600	Trial comparisons
Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) vs Pembrolizumab + Cisplatin +TS-1 (Cohort 2): Number of Participants Discontinuing From Study Treatment Due to AE(s)	3 of 54	3 of 46	100	NCT03382600	Trial comparisons
Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) vs Pembrolizumab + Cisplatin +TS-1 (Cohort 2): deaths from any cause	3 of 54	0 of 46	100	NCT03382600	Trial comparisons
Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) vs Pembrolizumab + Cisplatin +TS-1 (Cohort 2): serious adverse events	27 of 54	22 of 46	100	NCT03382600	Trial comparisons

Papers from its trials30

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21060024	RESULT	1	PubMed
18270704	RESULT	1	PubMed
42223130	DERIVED	1	PubMed
41979863	DERIVED	1	PubMed
41811823	DERIVED	1	PubMed
41766168	DERIVED	1	PubMed
40341124	DERIVED	3	PubMed
40340830	DERIVED	1	PubMed
39637944	DERIVED	1	PubMed
39162872	DERIVED	1	PubMed

1 to 10 of 30

See all 30 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021085

GET https://conductscience.org/api/diseases/v1/MONDO_0021085/drugs?page=2

API reference For AI assistants